AAVogen focuses on developing gene therapies to treat muscle-wasting diseases. Their unique science involves engineering novel adeno-associated viral (AAV) vectors. These vectors are designed to specifically target muscle tissue while avoiding the liver, a common side effect of traditional AAV-based therapies. By optimizing these vectors, AAVogen aims to deliver therapeutic genes directly to muscle cells, potentially leading to significant improvements in muscle strength, function, and overall quality of life for patients with debilitating muscle diseases.

AAVogen

Founded: 2015
Location: Rockville, Maryland
Employee range: 1-50
Clinical stage: Clin0
Therapy area: Inclusion body myositis
Drug types: MUS, NWL, GEN
Lead product: AVGN7
Funding: &lt;10M

Drug notes:

About:

Jobs: